Skip to Content
 

Healthcare Mergers and Acquisitions Panel

“Dealmaking to Access Novel Technologies and Gain Competitive Advantage in a Consolidating Healthcare Sector Earnings”

ISSUES

  • External growth strategies of Big Pharma and specialty pharma companies seeking to add breadth and depth to existing portfolios and to access novel compounds and technologies.
  • Focus of M&A activities of global medical technology companies to enhance growth prospects.
  • Diversification/growth strategies being pursued by major payors through the use of M&A, joint ventures, and partnerships.
  • Current M&A focus of hospitals and other providers to gain competitive advantage and economies of scale.
  • Role, focus, and impact of private equity firms in healthcare dealmaking.
  • Current state of the capital markets and its impact on healthcare deal flow.
  • How successful companies are organized to best identify, pursue, negotiate, and execute M&A and other business development initiatives.


Ken Hitchner ’92
Partner and Head of Healthcare Investment Banking
Goldman Sachs

Ken is global head of the Healthcare Banking Group and global co-head of the Technology, Media and Telecom Group. He serves on the Investment Banking Division Operating Committee and Client and Business Standards Committee. Ken joined Goldman Sachs in 1991 as a member of the Corporate Finance Department. In 1995, he joined the Healthcare Group as a founding member. Ken became head of Goldman Sachs’ global medical device banking practice in 1998 and the global pharmaceutical banking practice in 2001. He was named managing director in 2000 and partner in 2002.

Prior to joining the firm, Ken was a lieutenant commander and naval aviator in the US Navy. Ken is an adjunct professor at Columbia Business School and a trustee and member of the board of Meridian Health Systems and Monmouth University. He also serves on advisory councils at the University of Miami and the University of Colorado.

Rob Fraiman '85
Chief Executive Officer
Cain Brothers

Rob has served as CEO of Cain Brothers since January, 2010. He joined the firm in 2004 to head the Corporate Finance Group and serve as a member of the Executive Committee and Board of Directors.

He has been an investment banker for 27 years and previously was head of health care investment banking at BMO Capital Markets and co-founder of the health care investment banking group at Bear Stearns. He was with Bear Stearns for 16 years.

Rob has worked with clients in the health care services and medical technology industries throughout his career. He has been involved in several hundred investment banking transactions during his career, providing advice on mergers and acquisitions, strategic development, and equity and debt capital raising in the public and private placement markets.  He was Cain Brothers’ lead banker on the groundbreaking 2010 Sale of Caritas Christi Health Care by Cerberus Capital, which was named “Health Care Deal of the Year” by the leading financial industry publication, IDD.

Rob is a member of the Board of Directors of Grand Street Settlement, a community social services organization in New York City. He is a graduate of Colgate University with a BA in History and earned an MBA at Columbia Business School. Rob resides in Westchester County

Demetrios Kydonieus, Esq.
Vice President, Strategy, Alliances and Transactions
Bristol Myers-Squibb Company

Demetrios Kydonieus, Esq. is Vice President, Strategy, Alliances and Transactions at Bristol Myers-Squibb Company. He manages the Strategic Transaction Program Management Office (PMO) and has responsibility for driving all global M&A activities and mature brand divestitures.

Demetrios began working at BMS in 1998 as Director, Worldwide Regulatory Affairs in the Health Care Group. After leaving the Health Care Group, Demetrios joined the Corporate Strategy and Issues Management Group as Director, Business Risk Management, where he identified and helped manage the largest risks to the BMS strategy. Demetrios moved with his family to Boston as Division Counsel for the Medical Imaging division, where he was a member of the business unit's Executive Team and helped lead the divestiture of the business. Returning from Medical Imaging, Demetrios leveraged his M&A experience and joined the Corporate Development Legal Group where he was instrumental in divesting six billion in mature brands and other businesses.

Demetrios earned his Juris Doctor degree from Quinnipiac University School of Law and his Masters of Business Administration from Duke University, Fuqua School of Business.

Demetrios lives outside of Princeton, New Jersey with his wife Angela and their three children.

Rachel Winokur
Head of Business Development, Emerging Businesses
Aetna

Rachel Winokur leads the Business Development organization for Emerging Businesses, the group responsible for identifying, developing and growing non-insurance healthcare businesses within Aetna.  Rachel has responsibility for strategy, mergers and acquisitions, and development and oversight of these new businesses as they progress to commercial launch.  Rachel joined Aetna from the Carlyle Group, a global private equity firm, where she invested in healthcare companies for Carlyle’s U.S. Growth Equity Fund.  Previously, Rachel was vice president and a corporate officer of Business Development for Datascope, a publicly-traded medical devices company focused on cardiovascular medicine and critical care.  Prior to that role, she spent several years in business development and operations with Bertelsmann, a global media company.  Rachel started her career at Goldman Sachs in the mergers and acquisitions and equity capital markets departments.

Rachel received her MBA from Stanford University’s Graduate School of Business and her bachelor’s degree in Engineering (Biomedical Engineering and Electrical Engineering) with honors from Duke University.

Andrew Weisenfeld
Senior Managing Director
MTS Health Partners

Andrew has been an investment banker since 1989. Andrew became a senior member of the MTS team in January 2008, primarily responsible for the development of the life sciences and medical technology practices. Prior to joining, Andrew was a Managing Director in Banc of America Securities' Corporate and Investment Banking Healthcare Group. Andrew co-led the firm's life sciences practice, providing capital raising and strategic advisory services to both publicly traded and private companies. Prior to joining Bank of America in 2003, Andrew was a Managing Director at JP Morgan, leading its Healthcare M&A business across all sectors of healthcare since 1999. Andrew joined Chase Securities, a predecessor company to JP Morgan, in 1997. Prior to joining Chase, Andrew spent over five years in the M&A Group at Merrill Lynch. Throughout his career, Andrew has worked on a range of advisory transactions including acquisitions, sale transactions and strategic relationships. Andrew holds an MBA from The Wharton School at the University of Pennsylvania and a BS from Cornell University.

  Mary Amor
Director, Mergers & Acquisitions
Siemens Corporation

Mary is responsible for merger and acquisition activities of the Healthcare Sector in the Americas.  Prior to joining Siemens, Mary was a Managing Director in Mergers & Acquisitions with Citigroup Global Markets Inc.  Her mergers and acquisitions career began in Salomon Brothers Mergers and Acquisitions department post graduation from business school.  Prior to business school, Mary worked in strategy consulting.

Mary is a member of the Board of Directors of the New York City Mission Society, and serves on the Advisory Board of the Nichols Center for Applied Corporate Finance and Investment Banking at the University of Wisconsin.  She received her M.B.A. from the Tuck School of Business at Dartmouth, and her B.A. from Georgetown University.